



C

MD

MD

MD

MD

*

|| :

|| :



C :

C

C

RT-PCR

RT-PCR

% / % / % /

(%)

% / % / % / % /

C


HCV C :

()

*

E.mail: amn-bjd@msn.com

¹ Primer - specific



.() RNA (HCV) C
 .() nm
 HCV .()
 () /
 .()
 .() %
 HCV % .()
 .() HCV %
 HCV % / /
 HCV HCV .()
 HCV HCV % C
 HCV HCV .()
 C
 .()
 HCV

Archive of SID

² hepacivirus

³ Parafermalia

(% /) HCV

()

C

(% /) HIV (% /)

()

HbsAg

(± /) = AST / (± /) = ALT

(/ ± /) = ALP /

()

HCV

(% /) :

C

% / % / % /

PCR
() PCR (+) PCR

HCV

t

ALP,AST,ALT

HCV

(HCV)C

(%)	(%)	(%)	(%)	/ HCV
(% /)	(% /)	(% /)	(% /)	(% /)
(% /)	(% /)	(% /)	(% /)	(% /)
(% /)	(% /)	(% /)	(% /)	(% /)
(% /)	(% /)	(% /)	(% /)	(% /)
(% /)	(% /)	(% /)	(% /)	(% /)

(% /) (% /)

/ (+ /)

(% /)

(% /)

(% /)

HCV

(% /)

HCV

C


HCV

(% /)

(% /)

HCV

(% /)



.()
HCV

b a %
%

.() C

.()

C

a

(% /) a

C

.()

(% /)

.()

HCV

a

a % a

%

a

a

C

.()

a

(a)

VIII

a

a

b

.()

()

a a

.()

b

.()

b

.()

.()

a

(% /)

(non)

()

C

References:

- 1- Theodore D, Lemon SM. GB virus C, Hepatitis C virus, or human orphanflavivirus?. **Hepatology** 1997; 25:1285-6.
- 2- Seeff LB. Natural history of chronic hepatitis C. **Hepatology** 2002; 36: 535-46.
- 3- Arthur RR, Hassan NF, Abdallah MY, et al. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. **Trans R Soc Trop Med Hyg** 1997; 91:271-4.
- 4- Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: A 13-year follow-up study of hepatitis C virus markers. **Liver** 1993; 13: 274-8.
- 5- El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. **N Engl J Med** 1999; 340: 745-50.
- 6- Kim WR. The burden of hepatitis C in the United States. **Hepatology** 2002; 36 (1):593-8.
- 7- Thomas DL, Ray SC, Lemon SM. Hepatitis. In: Mandell GL, Bennett JE, Dolin R. **Mandell, Douglas and Bennetts: Principles and Practice of Infectious Diseases**. 6th ed. Elsevier Churchill Livingstone. 2005. 6th Edition.
- 8- Terrault NA. Sexual activity as a risk factor for hepatitis C. **Hepatology** 2002; 36(1): 99-105.
- 9- Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, Management, and treatment of Hepatitis C. **Hepatology** 2004; 39:1147-75.
- 10- Hadziyannis S, Chienquer H, et al. Peginterferon alpha-2a in combination with ribavirin: efficacy and safety results from a phase III randomized double-blind multicentre study examining effect of duration of treatment and ribavirin dose. **Ann Intern Med** 2004; 140: 346-55.
- 11- Ghavanin AA, Sabri MR. HbsAg and hepatitis C antibodies among blood donors in the Islamic Republic of Iran. **East Mediterr Health J** 2000; 6:1114-6.
- 12- Ansari MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in Iran-Rasht. **J Virol Hepatol** 2002; 9:390-2.
- 13- Pawlotsky J M, Tsakiris L, Roudot-Thoraval F, et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. **J Infect Dis** 1995; 17:1607-10.
- 14- Samimi-Rad K, Rakhshandeh N, et al. Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NSSB region. **J of Med Virol** 2004; 74:246-52.

- 15- Abacioglu YH, Davidson F, et al. The distribution of hepatitis C virus genotypes in Turkish patients. **J Virol Hepatol** 1995; 2: 297-301.
- 16- De Carvalho A, Martinho A, et al. HCV genotype, liver histopathology and immunologic profile in four groups of patients. **Acta Med Port** 2000; 13(3):67-75.
- 17- Harris KA, Gilbam C, et al. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. **J Med Virol** 1999; 58:127-31.
- 18- Chamberlain RW, Adams N, et al. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant in the Middle East. **J Gen Virol** 1997; 78:1341-7.
- 19- Nasir K, Naila A, et al. Serotype 3 is most common hepatitis C serotype in Pakistan, however significant numbers are untypable. **Hepatology** 2003; 38: 270-1.
- 20- Stephanos J, Hadziyannis S, Koskinas J. Difference in epidemiology, liver disease and treatment response among HCV genotypes. **Hepatology Research** 2004; 29:129-35.

Archive of SID